<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6127">
  <stage>Registered</stage>
  <submitdate>23/08/2002</submitdate>
  <approvaldate>23/08/2002</approvaldate>
  <nctid>NCT00044278</nctid>
  <trial_identification>
    <studytitle>Pediatric Epilepsy Study in Subjects 1-24 Months</studytitle>
    <scientifictitle>An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>LAM20007</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Epilepsy</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Epilepsy</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - lamotrigine

Treatment: drugs: lamotrigine


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with overall, serious, drug-related treatment emergent adverse events and adverse events leading to premature study discontinuation</outcome>
      <timepoint>43 Months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in vital signs -heart rate (HR)</outcome>
      <timepoint>Up to 43 Months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in vital signs - weight (WT)</outcome>
      <timepoint>Up to 43 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in vital signs - height (HT)</outcome>
      <timepoint>Up to 43 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in vital signs - head circumference (HC)</outcome>
      <timepoint>Up to 43 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in clinical chemistry parameters including Albumin and Total protein</outcome>
      <timepoint>Up to month 43</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in clinical chemistry parameters including alkaline phosphatase, Alanine transaminase (ALT), and Aspartate Aminotransferase (AST)</outcome>
      <timepoint>Up to 43 moths</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in clinical chemistry parameters including total bilirubin and creatinine</outcome>
      <timepoint>Up to 43 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in clinical chemistry parameters including glucose (glu), potassium (K), sodium (Na) and urea</outcome>
      <timepoint>Up to 43 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in hematological parameters including bands, basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and total white blood cells (WBC)</outcome>
      <timepoint>Up to 43 moths</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in Hemoglobin (Hb)</outcome>
      <timepoint>Up to 43 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in Mean corpuscular hemoglobin (MCH)</outcome>
      <timepoint>Up to 43 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in Mean corpuscular hemoglobin concentration (MCHC)</outcome>
      <timepoint>Up to 43 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in mean corpuscular volume (MCv)</outcome>
      <timepoint>Up to 43 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change from baseline in red blood cells (RBC)</outcome>
      <timepoint>Up to 43 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with treatment emergent neurological abnormalities</outcome>
      <timepoint>Up to 43 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with treatment emergent clinically significant ECG abnormalities</outcome>
      <timepoint>Up to 43 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with potentially clinically significant change in hematology parameters</outcome>
      <timepoint>Up to 43 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with potentially clinically significant change in clinical chemistry parameters</outcome>
      <timepoint>Up to 43 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with potentially clinically significant change in vital signs</outcome>
      <timepoint>Up to 43 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mean percentage change in seizure frequency between the Historical Baseline Phase and over the course of the 48-week Treatment Phase</outcome>
      <timepoint>Up to 48 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Investigator's assessment of the participant's overall clinical status</outcome>
      <timepoint>Up to 43 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Maximal plasma concentration (Cmax) in serum and saliva of Lamicital -naïve participants</outcome>
      <timepoint>Week 6</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Must have completed the Open-Label Phase of protocol LAM20006 or meet criteria for
             LAMICTAL naive subjects as follows:

          -  A confident diagnosis of epilepsy.

          -  4 or more partial seizures per month.

          -  current treatment with 1 or 2 anti-epileptic drugs.</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Month</inclusiveminagetype>
    <inclusivemaxage>24</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Has seizures not related to epilepsy.

          -  Has a surgically implanted and functioning vagal nerve stimulator.

          -  Has previously been treated with lamotrigine.

          -  Is currently taking felbamate, ACTH (adrenocorticotrophic hormone) or is on the
             ketogenic diet.

          -  Use of experimental medication within 30 days of enrollment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2000</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>197</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>GSK Investigational Site - Parkville, Melbourne</hospital>
    <postcode>3050 - Parkville, Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad Autónoma de Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tartu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Reims Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Miskolc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Pécs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Campania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Sicilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Veneto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state>Beirut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Kaunas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Coimbra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>SanJuan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Presov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with
      partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age
      who have never received LAMICTAL(LAMICTAL-naive). For LAMICTAL-naive subjects, LAMICTAL will
      be added to the subject's current epilepsy medications.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00044278</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>